The Healthcare Technology Accelerator Facility (HTAF) at the University of Edinburgh has achieved a significant regulatory milestone: Medicines and Healthcare products Regulatory Agency (MHRA) approval to import and manufacture Investigational Medicinal Products for use in human clinical trials.
This achievement represents years of work building quality management systems, validated processes, and the specialised expertise needed to manufacture clinical-grade products within an academic setting. For MicroTex, embedded within this wider translational ecosystem, the approval marks a critical enabler for accelerating our research from laboratory innovation to clinical evaluation.
What This Means
The Good Manufacturing Practice (GMP) Facility within HTAF now provides a faster, regulated route to take novel discoveries—including new formulations and active pharmaceutical ingredients—through late-stage development and into early-stage clinical evaluation. A particular strength of the facility is its ability to conduct small batch manufacturing, essential for projects like MicroTex where precision and agility matter. The facility consists of a warehouse, Active Pharmaceutical Ingredient (API) laboratory, quality control laboratory, and three segregated cleanrooms for manufacturing both sterile and non-sterile drug products. Each laboratory is overseen by highly qualified chemists and quality assurance staff with extensive experience supporting academic and commercial partners.
The MicroTex Connection
For MicroTex, this approval is directly relevant to our work developing platforms for Intra-Target Microdosing. While our engineering teams develop novel medical devices for precise drug delivery to the lungs and cornea, HTAF’s GMP capability ensures we have pharmaceutical assets ready to test—manufactured to the exacting standards required for human clinical trials.
HTAF sits within the University of Edinburgh’s Institute for Regeneration and Repair at Edinburgh BioQuarter, alongside several interconnected centers accelerating healthcare innovation. This ecosystem approach means pharmaceutical development, medical device innovation, clinical expertise, and regulatory capability sit side by side, enabling faster translation from discovery to clinical evaluation.
Why This Matters Now
MicroTex’s goal is to enable earlier, better decision-making in drug development by testing compounds at the site of disease in Phase 0. This requires not just innovative delivery devices, but pharmaceutical assets manufactured to clinical standards. HTAF’s MHRA approval removes a significant bottleneck in that pathway.
For antimicrobial resistance—where the therapeutic pipeline is shrinking and time matters—the ability to rapidly manufacture small batches of investigational products and move them into early human studies could be transformative.
This milestone reflects the collaborative, translational approach at the heart of MicroTex: bringing together engineering innovation, pharmaceutical expertise, clinical medicine, and regulatory rigor to tackle some of healthcare’s most pressing challenges.